Skip to main content
Premium Trial:

Request an Annual Quote

Roche's First-Half Dx Sales Rise 7 Percent; Double-Digit Growth for Applied Science

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today reported that first-half 2010 sales for its diagnostics division increased 7 percent, with its applied science unit posting 11 percent growth for the period.

The Swiss pharmaceuticals, diagnostics, and research products giant reported overall revenues of CHF 24.64 billion ($23.6 billion), up 3 percent from CHF 24.01 billion for the first half of 2009.

Its diagnostics division had 7 percent sales growth to CHF 5.25 billion, with tissue diagnostics and applied science providing the strongest growth at 13 percent and 11 percent, respectively. The firm's molecular diagnostics sales increased 2 percent to CHF 604 million.

Roche said that within its applied science business, cell analysis products had particularly strong growth. The firm did not mention its sequencing products sales in a statement accompanying its financial results.

Roche's pharmaceutical sales were up 1 percent for the period at CHF 19.39 billion.

Overall, Roche's net income for the first half was up 37 percent at CHF 5.56 billion, or CHF 6.91 per share, from CHF 4.05 billion, or CHF 6.32 per share.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.